US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6562594B1
(en)
|
1999-09-29 |
2003-05-13 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US6238884B1
(en)
|
1995-12-07 |
2001-05-29 |
Diversa Corporation |
End selection in directed evolution
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6171820B1
(en)
|
1995-12-07 |
2001-01-09 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US6352842B1
(en)
|
1995-12-07 |
2002-03-05 |
Diversa Corporation |
Exonucease-mediated gene assembly in directed evolution
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
US6361974B1
(en)
|
1995-12-07 |
2002-03-26 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
ES2273415T3
(es)
*
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US20070059302A1
(en)
*
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
US6887674B1
(en)
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
WO2000034337A1
(en)
*
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
WO2000037502A2
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
BR0010017A
(pt)
|
1999-04-28 |
2002-06-11 |
Univ Texas |
Composições e processos para o tratamento de câncer por inibição seletiva de vegf
|
TWI290146B
(en)
*
|
1999-07-29 |
2007-11-21 |
Dyax Corp |
Binding moieties for fibrin
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
EP1757311B1
(en)
|
1999-12-24 |
2009-02-11 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
JP2003518075A
(ja)
|
1999-12-24 |
2003-06-03 |
ジェネンテック・インコーポレーテッド |
生理活性化合物の消失半減期延長のための方法及び組成物
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
EP2075253A1
(en)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US6902718B2
(en)
|
2000-10-24 |
2005-06-07 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
|
US6989138B2
(en)
|
2000-10-24 |
2006-01-24 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
US7117096B2
(en)
|
2001-04-17 |
2006-10-03 |
Abmaxis, Inc. |
Structure-based selection and affinity maturation of antibody library
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
TWI240632B
(en)
|
2001-07-30 |
2005-10-01 |
Epix Medical Inc |
Purified peptides for peptide-based multimeric targeted contrast agents
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
HUP0600342A3
(en)
*
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
EP2048154B2
(en)
|
2002-02-05 |
2015-06-03 |
Genentech, Inc. |
Protein purification
|
AU2003265235A1
(en)
|
2002-04-26 |
2003-12-19 |
Genetech, Inc. |
Non-affinity purification of proteins
|
KR101086533B1
(ko)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
CA2491310C
(en)
|
2002-07-15 |
2015-10-06 |
Board Of Regents, The University Of Texas System |
Compositions comprising cell-impermeant duramycin derivatives
|
PT2314629E
(pt)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Produção recombinante de misturas de anticorpos
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
WO2004065417A2
(en)
*
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
ES2531125T3
(es)
|
2003-02-03 |
2015-03-10 |
Ibio Inc |
Sistema para la expresión de genes en plantas
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
JP2006521111A
(ja)
|
2003-03-12 |
2006-09-21 |
バスジーン セラピューティクス, インコーポレイテッド |
血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
|
WO2008109433A2
(en)
|
2007-03-02 |
2008-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
BRPI0410562B8
(pt)
|
2003-05-22 |
2021-05-25 |
Fralunhofer Usa Inc |
proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CA2526085A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
DK3095793T3
(da)
|
2003-07-28 |
2020-05-25 |
Genentech Inc |
Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7920906B2
(en)
|
2005-03-10 |
2011-04-05 |
Dexcom, Inc. |
System and methods for processing analyte sensor data for sensor calibration
|
DK1660057T3
(da)
|
2003-08-27 |
2012-08-20 |
Ophthotech Corp |
Kombinationsterapi til behandling af neovaskulære øjenlidelser
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US9247900B2
(en)
|
2004-07-13 |
2016-02-02 |
Dexcom, Inc. |
Analyte sensor
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー.ヴィー. |
結合タンパク質の混合物
|
EP2168986A3
(en)
|
2004-02-19 |
2010-07-28 |
Genentech, Inc. |
CDR-repaired antibodies
|
JP4960859B2
(ja)
|
2004-03-12 |
2012-06-27 |
バスジーン セラピューティクス,インコーポレイテッド |
血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
|
CN102718867A
(zh)
|
2004-03-12 |
2012-10-10 |
瓦斯基因治疗公司 |
结合ephb4、抑制血管发生和肿瘤生长的抗体
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
US20070045902A1
(en)
|
2004-07-13 |
2007-03-01 |
Brauker James H |
Analyte sensor
|
US8170803B2
(en)
|
2004-07-13 |
2012-05-01 |
Dexcom, Inc. |
Transcutaneous analyte sensor
|
PL1771474T3
(pl)
*
|
2004-07-20 |
2010-07-30 |
Genentech Inc |
Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
RU2442571C2
(ru)
|
2004-07-23 |
2012-02-20 |
Дженентек, Инк. |
Кристаллизация антител или их фрагментов
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
EP1799713B1
(en)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
NZ596663A
(en)
|
2004-10-21 |
2013-07-26 |
Genentech Inc |
Use of vegf antagonists in intraocular neovascular disease treatment
|
WO2006069403A2
(en)
|
2004-12-22 |
2006-06-29 |
Genentech, Inc. |
Methods for producing soluble multi-membrane-spanning proteins
|
JP5057994B2
(ja)
*
|
2005-01-06 |
2012-10-24 |
ジーイー・ヘルスケア・アクスイェ・セルスカプ |
光学イメージング
|
PL3248600T3
(pl)
|
2005-02-18 |
2020-09-07 |
Abraxis Bioscience, Llc |
Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US20060217311A1
(en)
|
2005-03-25 |
2006-09-28 |
Daniel Dix |
VEGF antagonist formulations
|
EP1879587A2
(en)
*
|
2005-04-15 |
2008-01-23 |
Schering Corporation |
Methods and compositions for treating or preventing cancer
|
JP2008543449A
(ja)
*
|
2005-06-17 |
2008-12-04 |
アボット・ラボラトリーズ |
変性脊椎疾患の改良型治療方法
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2611778C
(en)
*
|
2005-06-20 |
2012-11-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
BRPI0614475B8
(pt)
|
2005-08-03 |
2021-05-25 |
Fraunhofer Usa Inc |
polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
|
BRPI0615265A8
(pt)
|
2005-08-31 |
2018-03-06 |
Abraxis Bioscience Llc |
composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
E2epf ucp-vhl 상호작용 및 그 용도
|
EP2298308B1
(en)
*
|
2005-11-14 |
2013-01-16 |
University Of Southern California |
Integrin-binding small molecules
|
AU2006323412A1
(en)
*
|
2005-12-06 |
2007-06-14 |
Domantis Limited |
Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
|
AU2006326417B2
(en)
†
|
2005-12-16 |
2012-05-24 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
|
DK1973950T3
(en)
|
2006-01-05 |
2014-12-15 |
Genentech Inc |
ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
|
RU2451031C2
(ru)
|
2006-01-20 |
2012-05-20 |
Дженентек, Инк. |
Антитела к эфрину в2 и способы их применения
|
JP2009526526A
(ja)
|
2006-02-13 |
2009-07-23 |
フラウンホーファー ユーエスエー, インコーポレイテッド |
インフルエンザ抗原、ワクチン組成物、および関連する方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
DK1989231T3
(en)
|
2006-03-21 |
2015-08-24 |
Genentech Inc |
COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
|
UA95797C2
(ru)
*
|
2006-03-22 |
2011-09-12 |
Ф. Хоффманн-Ля Рош Аг |
Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
|
TW200812615A
(en)
*
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
MX2008012279A
(es)
*
|
2006-03-29 |
2008-10-08 |
Genentech Inc |
Diagnostico y tratamientos para tumores.
|
WO2007116360A2
(en)
|
2006-04-07 |
2007-10-18 |
The Procter & Gamble Company |
Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
|
KR20090027227A
(ko)
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-dll4 항체 및 이의 사용 방법
|
WO2007143689A2
(en)
*
|
2006-06-06 |
2007-12-13 |
Genentech, Inc. |
Compositions and methods for modulating vascular development
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
WO2008011513A2
(en)
|
2006-07-19 |
2008-01-24 |
The Cleveland Clinic Foundation |
Compounds and methods of modulating angiogenesis
|
CN100448892C
(zh)
*
|
2006-08-02 |
2009-01-07 |
中国人民解放军军事医学科学院基础医学研究所 |
抗肿瘤血管内皮生长因子受体vegf-r2抗原及其编码基因与应用
|
DK2056874T3
(da)
|
2006-08-21 |
2012-10-15 |
Hoffmann La Roche |
Tumorterapi med et anti-vegf-antistof
|
MX2009003229A
(es)
|
2006-09-29 |
2009-06-18 |
Oncomed Pharm Inc |
Composiciones y metodos para diagnosticar y tratar cancer.
|
DK2069798T3
(da)
|
2006-10-04 |
2014-06-16 |
Genentech Inc |
Elisa til vegf
|
US20110076279A1
(en)
*
|
2006-10-20 |
2011-03-31 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
US20080248033A1
(en)
*
|
2006-12-19 |
2008-10-09 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079302A2
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
NZ577933A
(en)
|
2007-01-22 |
2011-12-22 |
Genentech Inc |
Polyelectrolyte precipitation and purification of antibodies
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
PE20090245A1
(es)
|
2007-05-08 |
2009-03-17 |
Genentech Inc |
Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
|
ES2469743T3
(es)
|
2007-05-17 |
2014-06-18 |
Genentech, Inc. |
Inhibición de la metástasis tumoral por anticuerpos anti neuropilina 2
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
WO2009009759A2
(en)
|
2007-07-11 |
2009-01-15 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
WO2009023185A1
(en)
|
2007-08-13 |
2009-02-19 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
RU2498991C2
(ru)
*
|
2007-10-30 |
2013-11-20 |
Дженентек, Инк. |
Очистка антител с помощью катионообменной хроматографии
|
ES2554812T3
(es)
|
2007-11-09 |
2015-12-23 |
Genentech, Inc. |
Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
EP2644204B1
(en)
|
2008-03-18 |
2017-04-19 |
Genentech, Inc. |
Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
|
JP5425180B2
(ja)
*
|
2008-03-27 |
2014-02-26 |
ザイモジェネティクス, インコーポレイテッド |
PDGFRβおよびVEGF−Aを阻害するための組成物および方法
|
US8314213B2
(en)
*
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
PE20100054A1
(es)
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
CN102143976B
(zh)
*
|
2008-06-25 |
2015-11-25 |
艾斯巴技术-诺华有限责任公司 |
抑制vegf的稳定和可溶的抗体
|
RU2011104348A
(ru)
*
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
EP2321651B1
(en)
|
2008-07-23 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Identification of subjects being susceptible to anti-angiogenesis therapy
|
EP3604324B1
(en)
|
2008-08-14 |
2024-02-28 |
Genentech, Inc. |
Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
|
TW201012935A
(en)
*
|
2008-08-29 |
2010-04-01 |
Genentech Inc |
Diagnostics and treatments for VEGF-independent tumors
|
US20110318360A1
(en)
|
2008-09-05 |
2011-12-29 |
Duke University |
Anti-lipid antibodies
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
US8734803B2
(en)
|
2008-09-28 |
2014-05-27 |
Ibio Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
CN110317272A
(zh)
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
JP5954990B2
(ja)
|
2008-11-03 |
2016-07-20 |
モレキュラー・パートナーズ・アーゲーMolecular Partners Ag |
Vegf−aレセプター相互作用を阻害する結合タンパク質
|
CA2740242A1
(en)
|
2008-11-05 |
2010-05-14 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
HUE024872T2
(en)
|
2008-11-22 |
2016-02-29 |
Hoffmann La Roche |
Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
|
SG171446A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Stirred tank reactor and method
|
WO2010074702A1
(en)
|
2008-12-16 |
2010-07-01 |
Millipore Corporation |
Purification of proteins
|
SG172355A1
(en)
|
2008-12-23 |
2011-07-28 |
Genentech Inc |
Methods and compositions for diagnostic use in cancer patients
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
WO2010081838A2
(en)
|
2009-01-14 |
2010-07-22 |
Novartis Ag |
Sterile prefilled container
|
EP2393513B1
(en)
|
2009-02-06 |
2016-10-19 |
The General Hospital Corporation |
Methods of treating vascular lesions
|
CA2753294A1
(en)
|
2009-02-23 |
2010-08-26 |
Cytomx Therapeutics, Inc. |
Proproteins and methods of use thereof
|
EP2400992B1
(en)
|
2009-02-27 |
2015-07-22 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
EP2405750B1
(en)
|
2009-03-13 |
2018-05-09 |
Abraxis BioScience, LLC |
Combination therapy with thiocolchicine derivatives
|
PE20120770A1
(es)
|
2009-03-25 |
2012-07-10 |
Genentech Inc |
ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US8722860B2
(en)
*
|
2009-04-16 |
2014-05-13 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-α antibodies and their uses
|
MA33323B1
(fr)
*
|
2009-04-20 |
2012-06-01 |
Genentech Inc |
Thérapie adjuvante de cancer
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
US9309325B2
(en)
|
2009-05-07 |
2016-04-12 |
The Regents Of The University Of California |
Antibodies and methods of use thereof
|
CA2665956A1
(en)
*
|
2009-05-07 |
2010-11-07 |
Samir Patel |
Combination treatment for ocular diseases
|
RU2011149798A
(ru)
|
2009-05-08 |
2013-06-20 |
Дженентек, Инк. |
Гуманизированные анти-egfl7-антитела и способы их применения
|
JP6059013B2
(ja)
|
2009-05-08 |
2017-01-11 |
バクシネックス インコーポレーティッド |
抗cd100抗体およびこれを使用するための方法
|
JP5925677B2
(ja)
|
2009-06-15 |
2016-06-01 |
アイコン・ジェネティクス・ゲーエムベーハー |
キシロシルトランスフェラーゼ活性の欠損したベンサミアナタバコ(Nicotianabenthamiana)植物
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
MX2012000620A
(es)
|
2009-07-13 |
2012-01-27 |
Genentech Inc |
Metodos diagnostico y composiciones para tratamiento de cancer.
|
AR078060A1
(es)
|
2009-07-14 |
2011-10-12 |
Novartis Ag |
Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
KR20120089253A
(ko)
*
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
SG10201901417UA
(en)
|
2009-08-11 |
2019-03-28 |
Genentech Inc |
Production of proteins in glutamine-free cell culture media
|
CA2770321A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Biological markers for monitoring patient response to vegf antagonists
|
BR112012003346A2
(pt)
*
|
2009-08-15 |
2016-11-16 |
Genentech Inc |
metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
|
KR101764449B1
(ko)
|
2009-09-01 |
2017-08-02 |
제넨테크, 인크. |
변형된 단백질 a 용리를 통한 증진된 단백질 정제
|
WO2011028642A1
(en)
|
2009-09-04 |
2011-03-10 |
University Of Louisville Research Foundation, Inc. |
Genetic determinants of prostate cancer risk
|
CN102597776A
(zh)
|
2009-09-11 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌剂的可能性升高的患者的方法
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
MX2012002909A
(es)
|
2009-09-17 |
2012-04-19 |
Hoffmann La Roche |
Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
|
EP2483307A1
(en)
|
2009-09-29 |
2012-08-08 |
Fraunhofer USA, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
ES2895226T3
(es)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
|
MY176035A
(en)
|
2009-10-21 |
2020-07-22 |
Genentech Inc |
Genetic polymorphisms in age-related macular degeneration
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
RU2609658C2
(ru)
|
2009-12-21 |
2017-02-02 |
Дженентек, Инк. |
Состав, содержащий антитело
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
US20130178608A1
(en)
|
2009-12-29 |
2013-07-11 |
Samir Kulkarni |
Protein purification by ion exchange
|
US20120309056A1
(en)
|
2010-02-04 |
2012-12-06 |
Leon Arnaud |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
CA2787952C
(en)
|
2010-02-23 |
2016-07-26 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
CA2792125C
(en)
|
2010-03-22 |
2019-02-12 |
Genentech, Inc. |
Compositions and methods useful for stabilizing protein-containing formulations
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
KR20130028727A
(ko)
|
2010-03-29 |
2013-03-19 |
아브락시스 바이오사이언스, 엘엘씨 |
치료제의 약물 전달 및 유효성 향상 방법
|
NZ628423A
(en)
|
2010-03-29 |
2016-03-31 |
Abraxis Bioscience Llc |
Methods of treating cancer
|
US20130156755A1
(en)
|
2010-04-19 |
2013-06-20 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
CN102892791B
(zh)
|
2010-05-17 |
2017-05-17 |
Emd密理博公司 |
用于纯化生物分子的刺激响应性聚合物
|
RU2614125C2
(ru)
|
2010-05-28 |
2017-03-22 |
Дженентек, Инк. |
Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
SG186112A1
(en)
|
2010-06-04 |
2013-01-30 |
Abraxis Bioscience Llc |
Methods of treatment of pancreatic cancer
|
SG186783A1
(en)
|
2010-06-24 |
2013-02-28 |
Genentech Inc |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
BR112012030600A2
(pt)
*
|
2010-07-02 |
2017-07-11 |
Genentech Inc |
método de tratamento de deslocamento do epitélio pigmentar vascularizado da retina (vped) e de achatamento de um paciente
|
CA2803792A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
EP2824457A1
(en)
|
2010-07-19 |
2015-01-14 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
MY160445A
(en)
|
2010-08-03 |
2017-03-15 |
Abbvie Inc |
Dual Variable Domain Immunoglobulins And Uses Thereof
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
EP2640406A1
(en)
|
2010-11-15 |
2013-09-25 |
Five Prime Therapeutics, Inc. |
Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012095514A1
(en)
|
2011-01-14 |
2012-07-19 |
Vivalis |
Recombinant protein production system
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
EP3138581B1
(en)
|
2011-03-17 |
2019-01-02 |
The University of Birmingham |
Re-directed immunotherapy
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
CN103635192B
(zh)
|
2011-04-01 |
2017-07-04 |
基因泰克公司 |
Akt抑制剂化合物和化疗剂的组合以及使用方法
|
CN108341863A
(zh)
|
2011-04-20 |
2018-07-31 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
EP2732269B1
(en)
|
2011-07-12 |
2017-10-18 |
Epitomics, Inc. |
Facs-based method for obtaining an antibody sequence
|
EP2551348B1
(en)
|
2011-07-29 |
2014-09-24 |
Icon Genetics GmbH |
Production of galactosylated N-glycans in plants
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
BR112014007035B1
(pt)
|
2011-09-23 |
2021-05-04 |
Oncomed Pharmaceuticals, Inc |
anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo
|
AU2012320847B2
(en)
|
2011-10-04 |
2018-03-08 |
Icon Genetics Gmbh |
Nicotiana benthamiana plants deficient in fucosyltransferase activity
|
SG11201401458UA
(en)
|
2011-10-11 |
2014-07-30 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
EP2766044B1
(en)
*
|
2011-10-13 |
2019-12-11 |
Aerpio Therapeutics, Inc. |
Treatment of ocular disease
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
CA2858347C
(en)
|
2011-12-05 |
2020-07-07 |
Duke University |
V1v2 immunogens
|
US8790652B2
(en)
|
2011-12-06 |
2014-07-29 |
Vaccinex, Inc. |
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
|
TR201815709T4
(tr)
|
2011-12-22 |
2018-11-21 |
Hoffmann La Roche |
İyon değişim membranı kromatografisi.
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
RU2659173C2
(ru)
|
2012-01-13 |
2018-06-28 |
Дженентек, Инк. |
Биологические маркеры для идентификации пациентов для лечения антагонистами vegf
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
ES2617853T3
(es)
|
2012-02-27 |
2017-06-20 |
Universitat De Barcelona |
Compuestos resistentes a proteasas útiles como transportadores a través de la barrera hematoencefálica y construcciones de transportador-carga
|
RS58964B1
(sr)
|
2012-03-13 |
2019-08-30 |
Hoffmann La Roche |
Kombinovana terapija za lečenje karcinoma jajnika
|
EP2831261B1
(en)
|
2012-03-27 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Method for producing recombinant proteins with low levels of DHNA (1,4-dihydroxy-2-naphthoate)
|
AU2013240234B2
(en)
|
2012-03-30 |
2017-04-27 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
NZ772318A
(en)
|
2012-04-20 |
2023-06-30 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
US10494440B2
(en)
|
2012-05-11 |
2019-12-03 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
WO2013170182A1
(en)
|
2012-05-11 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with an hsp90 inhibitory compound
|
SG11201407859YA
(en)
|
2012-05-31 |
2014-12-30 |
Genentech Inc |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
MA42648B1
(fr)
|
2012-06-01 |
2019-10-31 |
Novartis Ag |
Seringue
|
EP3545968A1
(en)
|
2012-06-08 |
2019-10-02 |
F. Hoffmann-La Roche AG |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
HRP20211641T1
(hr)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
|
SG11201500903XA
(en)
|
2012-08-07 |
2015-03-30 |
Genentech Inc |
Combination therapy for the treatment of glioblastoma
|
AR092630A1
(es)
|
2012-09-19 |
2015-04-29 |
Genentech Inc |
Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
CA2890190A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
JP2016505528A
(ja)
|
2012-11-16 |
2016-02-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
KR20150095684A
(ko)
|
2012-12-18 |
2015-08-21 |
노파르티스 아게 |
히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
|
CN104994885B
(zh)
|
2012-12-19 |
2017-09-29 |
基因泰克公司 |
用于放射性卤素蛋白质标记的方法和组合物
|
US9770426B2
(en)
|
2013-01-11 |
2017-09-26 |
Massachusetts Eye And Ear Infirmary |
CYP450 lipid metabolites reduce inflammation and angiogenesis
|
US9682154B2
(en)
|
2013-02-04 |
2017-06-20 |
Vascular Biogenics Ltd. |
Methods of inducing responsiveness to anti-angiogenic agent
|
WO2014124487A1
(en)
|
2013-02-18 |
2014-08-21 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
BR112015022210A8
(pt)
|
2013-03-13 |
2018-01-23 |
Genentech Inc |
formulações de anticorpo
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
EP2968544A4
(en)
|
2013-03-15 |
2016-10-12 |
Hoffmann La Roche |
CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
KR20210094669A
(ko)
|
2013-04-29 |
2021-07-29 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
EP3252171B8
(en)
|
2013-05-23 |
2021-12-15 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
KR101541478B1
(ko)
*
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
CA2916245C
(en)
|
2013-06-25 |
2023-01-24 |
Vaccinex, Inc. |
Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
|
KR20230152151A
(ko)
|
2013-07-12 |
2023-11-02 |
이베릭 바이오, 인크. |
안과적 질환을 치료하거나 예방하기 위한 방법
|
KR20180021234A
(ko)
|
2013-08-12 |
2018-02-28 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
NZ630881A
(en)
|
2013-10-10 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treatment of atherosclerosis
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
NZ630892A
(en)
|
2013-10-21 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
|
JP6546587B2
(ja)
|
2013-10-25 |
2019-07-17 |
アクセレロン ファーマ インコーポレイテッドAcceleron Pharma,Inc. |
線維性疾患を処置するためのエンドグリンポリペプチド
|
EP3071181B1
(en)
|
2013-11-18 |
2021-03-24 |
Formycon AG |
Pharmaceutical composition of an anti-vegf antibody
|
JP6745218B2
(ja)
|
2013-11-27 |
2020-08-26 |
レッドウッド バイオサイエンス, インコーポレイテッド |
ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
|
MX2015014724A
(es)
*
|
2013-12-31 |
2016-06-02 |
Dev Center Biotechnology |
Anticuerpos anti-factor de crecimiento endotelial vascular (vegf) y uso de los mismos.
|
KR20160104636A
(ko)
|
2014-01-15 |
2016-09-05 |
에프. 호프만-라 로슈 아게 |
단백질 A-결합이 개선된 Fc-영역 변이체
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
MX2016010505A
(es)
|
2014-02-14 |
2017-04-13 |
S Chi Andrew |
Metodos mejorados para el tratamiento de canceres vascularizantes.
|
JP6666848B2
(ja)
|
2014-02-18 |
2020-03-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nrp−1/obr複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物
|
EP3110941A4
(en)
|
2014-02-25 |
2017-10-18 |
Dr. Reddy's Laboratories Ltd. |
Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
|
KR101921552B1
(ko)
|
2014-03-10 |
2018-11-23 |
리히터 게데온 닐트. |
사전 세정 단계를 이용하는 면역글로불린 정제
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
WO2015168468A1
(en)
|
2014-05-01 |
2015-11-05 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
EP3143044A1
(en)
|
2014-05-12 |
2017-03-22 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
CA2949121A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
EP3151830A4
(en)
|
2014-06-06 |
2018-02-07 |
Redwood Bioscience, Inc. |
Anti-her2 antibody-maytansine conjugates and methods of use thereof
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
BR112017000142B1
(pt)
|
2014-07-09 |
2021-08-17 |
Genentech, Inc |
Métodos para melhorar a recuperação por descongelamento de bancos de células e para congelamento de células cho para armazenamento, grupo de células cho para o congelamento de células de mamíferos, e banco de células
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
CN105330739B
(zh)
*
|
2014-08-12 |
2020-12-25 |
中美华世通生物医药科技(武汉)有限公司 |
与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
EP3200775B1
(en)
|
2014-10-03 |
2019-11-20 |
Novartis AG |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
BR112017007379A2
(pt)
|
2014-10-14 |
2017-12-19 |
Dana Farber Cancer Inst Inc |
moléculas de anticorpo para pd-l1 e usos das mesmas
|
EP3207128B1
(en)
|
2014-10-17 |
2022-07-27 |
Kodiak Sciences Inc. |
Butyrylcholinesterase zwitterionic polymer conjugates
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
HUE057653T2
(hu)
|
2014-12-11 |
2022-05-28 |
Bayer Healthcare Llc |
Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
WO2016120753A1
(en)
*
|
2015-01-28 |
2016-08-04 |
Pfizer Inc. |
Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
RU2749674C2
(ru)
|
2015-07-29 |
2021-06-16 |
Аллерган, Инк. |
Антитела против ang-2, содержащие только тяжелую цепь
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
WO2017030909A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
WO2017034906A1
(en)
*
|
2015-08-21 |
2017-03-02 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US10172875B2
(en)
|
2015-09-17 |
2019-01-08 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-FOLR1 immunoconjugates
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
AU2016326609B2
(en)
|
2015-09-23 |
2023-03-09 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
JP6835836B2
(ja)
|
2015-10-13 |
2021-02-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
脈絡膜血管新生の処置のための方法及び医薬組成物
|
JP2018531980A
(ja)
|
2015-10-30 |
2018-11-01 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体製剤
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
ES2870141T3
(es)
|
2015-10-30 |
2021-10-26 |
Hoffmann La Roche |
Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
KR20180069070A
(ko)
|
2015-11-03 |
2018-06-22 |
얀센 바이오테크 인코포레이티드 |
Tim-3과 특이적으로 결합하는 항체 및 그의 용도
|
WO2017079419A1
(en)
|
2015-11-05 |
2017-05-11 |
The Regents Of The University Of California |
Cells labelled with lipid conjugates and methods of use thereof
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
MX2018006139A
(es)
|
2015-11-18 |
2019-03-14 |
Sio2 Medical Products Inc |
Envase farmaceutico para formulaciones oftalmicas.
|
US20180326126A1
(en)
|
2015-11-18 |
2018-11-15 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
SI3384049T1
(sl)
|
2015-12-03 |
2023-10-30 |
Regeneron Pharmaceuticals, Inc. |
Postopki povezovanja genetskih različic s kliničnim izidom pri bolnikih s starostno degeneracijo makule, zdravljenih s proti-VEGF
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
EP3432927A4
(en)
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
MX2018011834A
(es)
|
2016-03-29 |
2019-03-06 |
Geltor Inc |
Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1.
|
EP3443350B1
(en)
|
2016-04-15 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック, インコーポレイテッド |
がんをモニタリングし治療するための方法
|
LT4019019T
(lt)
|
2016-05-20 |
2024-06-25 |
Biohaven Therapeutics Ltd. |
Riluzolo, riluzolo provaistų arba riluzolo analogų naudojimas kartu su imunoterapijos rūšimis vėžio formų gydymui
|
CN109890982B
(zh)
|
2016-07-08 |
2023-07-07 |
基因泰克公司 |
通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
|
EP3482205A1
(en)
|
2016-07-08 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
EP3487518A4
(en)
|
2016-07-20 |
2020-08-12 |
Aerpio Therapeutics LLC |
HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
|
CN106222129A
(zh)
*
|
2016-07-29 |
2016-12-14 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
EP3496752B1
(en)
|
2016-08-12 |
2022-05-18 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
EP3783022A3
(en)
|
2016-08-23 |
2021-06-30 |
MedImmune Limited |
Anti-vegf-a antibodies and uses thereof
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗robo4抗体と他剤を含む組成物
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
EP3565839A4
(en)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
CHECKPOINT REGULATOR ANTAGONISTS
|
EP3568150A4
(en)
|
2017-01-10 |
2020-12-02 |
Xcella Biosciences, Inc. |
POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
KR20190134631A
(ko)
|
2017-03-01 |
2019-12-04 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
KR20240049657A
(ko)
*
|
2017-03-24 |
2024-04-16 |
카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 |
재조합 항체 단편을 정제하는 방법
|
EP3606527A1
(en)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma agonist for treatment of progressive supranuclear palsy
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
JP7282689B2
(ja)
|
2017-05-19 |
2023-05-29 |
カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ |
リフォールディングした組み換えヒト化ラニビズマブの製造方法
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
US20200237997A1
(en)
|
2017-05-24 |
2020-07-30 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
CN118307674A
(zh)
|
2017-06-22 |
2024-07-09 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
US11931327B2
(en)
|
2017-07-04 |
2024-03-19 |
Daiichi Sankyo Company, Limited |
Drug for retinal degenerative disease associated with photoreceptor degeneration
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
WO2019057946A1
(en)
|
2017-09-25 |
2019-03-28 |
F. Hoffmann-La Roche Ag |
MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
CN111356480A
(zh)
|
2017-10-20 |
2020-06-30 |
脉管生物生长有限公司 |
用于抗血管生成剂疗法的诊断方法
|
SG11202005618WA
(en)
|
2017-12-19 |
2020-07-29 |
Akouos Inc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
JP2021508471A
(ja)
|
2017-12-29 |
2021-03-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗vegf抗体のvegf受容体遮断選択性を改善する方法
|
CN110283248B
(zh)
*
|
2018-01-05 |
2020-07-28 |
百奥泰生物制药股份有限公司 |
一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
|
JP7005772B2
(ja)
|
2018-02-06 |
2022-02-10 |
エフ.ホフマン-ラ ロシュ アーゲー |
眼科疾患の処置
|
SG11202007927WA
(en)
|
2018-03-09 |
2020-09-29 |
Agenus Inc |
Anti-cd73 antibodies and methods of use thereof
|
CN111989095A
(zh)
|
2018-04-16 |
2020-11-24 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
JOP20200275A1
(ar)
|
2018-05-10 |
2020-11-02 |
Regeneron Pharma |
صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019229116A1
(en)
|
2018-05-31 |
2019-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20210028222A
(ko)
|
2018-06-29 |
2021-03-11 |
젠선 바이오파마, 인코포레이티드 |
항종양 면역 체크포인트 조절 길항제
|
CA3104684A1
(en)
|
2018-07-03 |
2020-01-09 |
Bristol-Myers Squibb Company |
Methods of producing recombinant proteins
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
JP2022502367A
(ja)
|
2018-09-24 |
2022-01-11 |
エアーピオ ファーマシューティカルズ, インコーポレイテッド |
HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体
|
KR20210074341A
(ko)
|
2018-10-10 |
2021-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
CN109134651B
(zh)
*
|
2018-12-03 |
2019-02-22 |
上海复宏汉霖生物技术股份有限公司 |
一种抗vegf的单克隆抗体及其制备方法和应用
|
US20200207812A1
(en)
|
2018-12-07 |
2020-07-02 |
Coherus Biosciences, Inc. |
Methods for producing recombinant proteins
|
EP3897851A2
(en)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Twin immune cell engager
|
CN113784730A
(zh)
|
2019-03-13 |
2021-12-10 |
脉管生物生长有限公司 |
抗肿瘤疗法的方法
|
CA3133652A1
(en)
|
2019-04-01 |
2020-10-08 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
|
CN113993885A
(zh)
|
2019-04-12 |
2022-01-28 |
格尔托公司 |
重组弹性蛋白及其生产
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
KR20220004744A
(ko)
|
2019-05-03 |
2022-01-11 |
제넨테크, 인크. |
항-pd-l1 항체를 이용하여 암을 치료하는 방법
|
US20220211847A1
(en)
|
2019-05-06 |
2022-07-07 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
KR20220039777A
(ko)
|
2019-08-01 |
2022-03-29 |
브리스톨-마이어스 스큅 컴퍼니 |
유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
JP2022553640A
(ja)
|
2019-10-10 |
2022-12-26 |
コディアック サイエンシーズ インコーポレイテッド |
眼障害を処置する方法
|
WO2021072210A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods of purifying ranibizumab or a ranibizumab variant
|
WO2021072182A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods for producing ranibizumab
|
US20230022576A1
(en)
|
2019-11-19 |
2023-01-26 |
Protalix Ltd. |
Removal of constructs from transformed cells
|
BR112022010069A2
(pt)
|
2019-11-25 |
2022-09-06 |
Akeso Biopharma Inc |
Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica
|
WO2021180818A1
(en)
|
2020-03-11 |
2021-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
|
WO2021183849A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
WO2022013787A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
JP2023542924A
(ja)
|
2020-09-22 |
2023-10-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
治療タンパク質を生産するための方法
|
WO2022074646A1
(en)
|
2020-10-05 |
2022-04-14 |
Protalix Ltd. |
Dicer-like knock-out plant cells
|
CA3198668A1
(en)
|
2020-10-15 |
2022-04-21 |
Genentech, Inc. |
Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
|
EP4243828A1
(en)
|
2020-11-13 |
2023-09-20 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
|
MX2023006451A
(es)
|
2020-12-01 |
2023-06-15 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
|
US20220249639A1
(en)
|
2021-01-22 |
2022-08-11 |
Dcprime B.V. |
Methods of tumor vaccination
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
EP4304633A1
(en)
|
2021-03-12 |
2024-01-17 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
CA3193662A1
(en)
|
2021-03-12 |
2022-09-15 |
Akeso Biopharma, Inc. |
Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
|
EP4330436A1
(en)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
TW202313096A
(zh)
|
2021-05-28 |
2023-04-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
衣殼變異的重組腺相關病毒及其應用
|
US20220389120A1
(en)
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
CA3223534A1
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CA3224180A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
EP4386004A1
(en)
|
2021-08-13 |
2024-06-19 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-vegf a and -vegf c bispecific antibody and use thereof
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
WO2024051223A1
(zh)
|
2022-09-09 |
2024-03-14 |
中山康方生物医药有限公司 |
药物组合及用途
|